SOFINNOVA-PARTNERS
3.3.2021 06:02:08 CET | Business Wire | Press release
Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the final close of the Sofinnova Crossover Fund at €445 million ($540 million USD). The fund was oversubscribed and significantly exceeded its target. This capital raise positions Sofinnova Partners as the largest crossover investor in Europe dedicated to late-stage biopharma and medtech investments.
The fund will maintain its focus on European clinical-stage companies needing scale-up capital and will also support best-in-class companies in the U.S. and elsewhere. The fund has, to date, invested in 10 high-profile companies developing unique products that address major unmet clinical needs. The initial portfolio has demonstrated outstanding progress since inception, with the majority of investments reaching positive clinical trial milestones and raising large financings, including two NASDAQ IPOs of European companies.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, commented: “European biopharma and medtech companies have matured tremendously in the last decade. Sofinnova Partners was the first European VC to seize the opportunity to unlock the potential of these high-growth start-ups by providing late-stage capital, building on our decades of experience funding innovative life science companies. With over €2 billion of assets under management dedicated to life science investing and an outstanding international team, Sofinnova Partners continues its expansion to partner with ambitious entrepreneurs across Europe, from company creation to late-stage developments.”
Cédric Moreau, Partner in the Sofinnova Crossover Fund, commented: “We are grateful for the continuing support of our existing and new limited partners from all over the world who have helped us reach a target significantly beyond our initial objectives. The Sofinnova Crossover Fund is the largest of its kind in Europe and the only one with a team solely dedicated to growth-stage opportunities in healthcare. There has never been more awareness of the importance of investing in our collective health and future, and we are honored to contribute to this endeavor through this fund strategy.”
The Sofinnova Crossover Fund was recognized as a front runner in this domain in the 2019 “Tibi Report” commissioned by the French government as an initiative to fuel later-stage companies in Europe.1 It was subsequently granted the “Tibi” designation, making it eligible to apply for access to €6 billion in funds earmarked for this objective, which helped attract key French institutions as limited partners.
The Sofinnova Crossover Fund has expanded its team recently and, operating from Paris and London, continues to see an exceptional flow of new investment opportunities, bolstered by the firm’s extensive global network, its leading role in Europe, and the strength of its multi-fund life sciences strategy.
Triago acted as placement agent and Clifford Chance acted as legal counsel.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: www.sofinnovapartners.com
______________________
1
The Tibi Report was written by the Professor of Economics, Philippe Tibi, who highlighted the crucial need for scale-up financing for high-growth companies in France and Europe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302006092/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla Announces Reseller Program to Help Game Developers Unlock New Revenue Streams in Local Markets5.3.2026 18:00:00 CET | Press release
Game Developers And Publishers Can Now Reach More Players By Partnering with Official Distributors And Resellers Globally Without Building Local Infrastructure Xsolla, a leading global video game commerce company, today announced the Xsolla Reseller Program, a new product designed to help game developers scale and capture untapped revenue in local markets with no development needed. The program launches with a curated cohort of resellers and distributors in Southeast Asia and Latin America, with expansion into additional regions throughout 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305047070/en/ Graphic: Xsolla As game developers pursue global growth, they face a fundamental infrastructure challenge: billions of dollars in revenue remain untapped in emerging, cash-dependent economies, such as Southeast Asia, Latin America, the Middle East, and North Africa, where players purchase digital content through local di
Andersen Consulting styrker sine kompetencer inden for cybersikkerhed gennem samarbejde med A3Sec5.3.2026 17:16:00 CET | Pressemeddelelse
Andersen Consulting styrker sine tilbud inden for cybersikkerhed og teknologisk transformation gennem en samarbejdsaftale med A3Sec, et firma, der specialiserer sig i datadrevet trusselsdetektion, hændelsesrespons og exposure management. Med hovedsæde i Spanien og kontorer i Mexico og Colombia har A3Sec mere end 14 års erfaring med at hjælpe offentlige og private organisationer inden for finans, telekommunikation, energi, den offentlige sektor og erhvervslivet med at sikre deres digitale aktiver. Virksomheden driver sit Security and Digital Surveillance Center® (CSVD®) døgnet rundt med et team på over 180 cybersikkerhedseksperter og betjener mere end 280 kunder verden over. Firmaet leverer integrerede cybersikkerhedstjenester, herunder managed detection and response, cybertelemetri, trusselsanalyse og krisestyring, og hjælper kunder med at styrke deres robusthed og omdanne risiko til en strategisk fordel, samtidig med at de effektivt håndterer eksponering og minimerer risiko. "Vores fo
Xsolla Agency Launches to Empower Creators Across Entertainment-Based Intellectual Property5.3.2026 16:23:00 CET | Press release
New Service Simplifies Access to Premium IP Licensing, Driving Discoverability, Player Engagement, and Revenue for Game Developers Xsolla, a global video game commerce company, today launched Xsolla Agency, a comprehensive service connecting game developers with premium entertainment-based intellectual property (IP). The integrated offering addresses critical challenges for game creators: access to world-class IP, global monetization capabilities, and the operational infrastructure needed to build sustainable businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305044119/en/ Graphic: Xsolla Xsolla Agency simplifies access to entertainment-based licenses through expert-led negotiations and industry relationships, offering affordable, monetization-focused deals structured for maximum ROI. Strategic IP partnerships increase discoverability, reduce user acquisition costs, and drive higher player spend through impactful
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures5.3.2026 16:00:00 CET | Press release
-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX--These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14 days), demonstrating the potential for JOURNAVX as a core element of opioid-free multimodal treatment for moderate-to-severe acute pain after aesthetic and reconstructive procedures. In contrast, the literature shows opioid-free rates of less than 10% with multimodal treatment without JOURNAVX. These dat
Onego Bio and Sigma Foods Enter Collaboration to Strengthen Egg Protein Innovation and Supply Resilience5.3.2026 16:00:00 CET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein, and Sigma Foods ("SIGMA"), a leading multinational food company, have entered into a collaboration agreement to evaluate the functionality and commercial potential of Bioalbumen®, a non-animal egg protein made with using precision fermentation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305756400/en/ The partnership focuses on advancing ingredient innovation while addressing urgent challenges in today’s egg supply chain—including volatility, rising prices, and avian flu-related disruptions. Bioalbumen® offers a shelf-stable, animal-free alternative that delivers the same functional, nutritional, and sensory performance as traditional eggs, while helping safeguard supply continuity for food manufacturers. Additionally, this collaboration supports Sigma’s commitment to offering safe, nutritious, and high-quality food, while driving science-based inno
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom